OPTIMAL
OPTIMAL Trial — ACC.26 Late-Breaking Clinical Trial
Presented by Adrian Banning — Oxford University Hospitals
Subspecialty: Interventional
Published in NEJM
Key Result
Late-breaking results from the OPTIMAL trial presented at ACC.26 — published in NEJM.
What did this trial find?
The OPTIMAL trial was described as a late-breaking clinical trial presented at ACC.26 and simultaneously published in NEJM, led by Adrian Banning from Oxford University Hospitals, in the interventional cardiology space. However, none of the source material provided contains any quotes or coverage related to this specific OPTIMAL trial. The search results returned information about entirely different studies with similar names (a pelvic organ prolapse trial, ophthalmology trials, oncology dose optimization discussions, and other unrelated content).
Why does this trial matter?
No relevant source material was found for the OPTIMAL trial presented by Adrian Banning at ACC.26 and published in NEJM. All search results pertained to entirely different studies with similar names (pelvic organ prolapse, ophthalmology, oncology dose optimization, etc.). Quote supply is completely absent for this trial.
Study Design
Randomized controlled trial
Clinical Implications
Full results published in NEJM.
Abstract
The OPTIMAL trial was presented as a late-breaking clinical trial at ACC.26 and simultaneously published in the New England Journal of Medicine.